SCRI-MSD Trial Delivery Deal: Infrastructure Signal, Zero Clinical Evidence to Anchor Verdict

SCRI and MSD Partner to Expand US Oncology Trial Access

Sarah Cannon Research Institute (SCRI) and Merck & Co (MSD) have announced a collaboration aimed at increasing patient access to oncology clinical trials at community sites across the US. The partnership will utilize SCRI’s Accelero delivery model, which is designed to enhance the reach and efficiency of cancer studies. This initiative seeks to address the growing complexity of oncology clinical studies, the need for precise patient selection, and the demand for faster access to new therapies by implementing efficient trial delivery approaches and advanced data methods within local communities.

• The collaboration between SCRI and MSD is specifically designed to tackle the increasing complexity of oncology clinical studies. Their goal is to enable more precise patient selection and accelerate access to innovative therapies for cancer patients, particularly within community settings throughout the United States.
• Central to this partnership is SCRI's Accelero delivery model, which integrates several key features to optimize trial operations. These include accelerated start-up processes for trial sites, advanced electronic data transfer systems that link electronic health records (EHR) with case report forms, and targeted initiatives to boost patient recruitment for oncology trials.
• The Accelero model has demonstrated significant operational efficiencies and improved patient engagement. It has been shown to reduce trial site activation times by up to 50% compared to conventional methods. Furthermore, the model has achieved enrollment rates that are 19% higher than the national average of 7%, while also leading to a 95% reduction in data changes.
• SCRI maintains an extensive network, comprising approximately 1,500 oncology physicians, which facilitates access to clinical studies at over 200 sites across more than 20 US states. Since its establishment, the institute has played a role in over 900 first-in-human clinical trials, underscoring its significant experience in early-phase research.

Navigating the Evolving Oncology Treatment Landscape

The oncology treatment landscape has undergone substantial transformation over the past five years, driven primarily by the expansion of immune checkpoint inhibitors (ICIs) across a broadening range of tumor types and the maturation of biomarker-driven patient selection strategies. ICIs targeting the PD-1/PD-L1 axis have achieved regulatory approval and clinical integration across multiple solid tumors. In endometrial carcinoma, pembrolizumab and dostarlimab received FDA approvals for patients with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), with trial data demonstrating meaningful survival benefits both in combination with chemotherapy in the first-line setting and alongside targeted agents such as lenvatinib in previously treated populations. In triple-negative breast cancer, the phase III IMpassion130 and KEYNOTE-355 trials established atezolizumab plus nab-paclitaxel and pembrolizumab plus chemotherapy, respectively, as standard options for PD-L1-positive metastatic disease. Gastrointestinal malignancies have similarly benefited: atezolizumab-bevacizumab and durvalumab-tremelimumab combinations have surpassed traditional systemic therapies in hepatocellular carcinoma, durvalumab-chemotherapy combinations have yielded incremental gains in biliary tract cancers, and PD-1 inhibitors have demonstrated improved overall survival and more favorable tolerability profiles versus chemotherapy in second-line esophageal cancer. In dMMR/MSI-H colorectal cancer, ICI efficacy has been particularly striking, with trials such as NICHE-2 reporting exceptional pathological response rates.

Molecular biomarker stratification has become indispensable to patient selection and treatment optimization. dMMR and MSI-H status — conferring elevated tumor mutational burden and heightened neoantigen production — remain the most robustly validated predictors of ICI response across tumor types. POLE mutations, which drive hypermutation and increased immunogenicity, represent an additional predictive marker for favorable ICI outcomes. PD-L1 expression and tumor mutational burden continue to show variable and context-dependent correlations with response, underscoring the need for further standardization. Beyond biomarker refinement, the field has seen the emergence of novel immune checkpoint targets and evolving treatment sequencing strategies. The FDA approval of nivolumab plus relatlimab (Opdualag) — the first LAG-3 blocking antibody combination — for unresectable or metastatic melanoma marked a meaningful advance, with the combination more than doubling median progression-free survival compared to nivolumab monotherapy (10.1 months versus 4.6 months). The timing of immunotherapy delivery has also been revisited: the randomized phase II SWOG S1801 trial demonstrated a 42% reduction in two-year event-free survival risk with neoadjuvant versus adjuvant pembrolizumab in resectable stage IIIB–IV melanoma (72% versus 49%; HR 0.58; P = .004), effectively establishing neoadjuvant single-agent ICI as a new standard of care in this setting.

Despite these advances, critical limitations temper the overall trajectory of progress. Resistance mechanisms in subsets of dMMR/MSI-H tumors, near-absent efficacy in proficient mismatch repair (pMMR) populations, and persistent immune evasion driven by tumor heterogeneity continue to constrain response rates across the majority of gastrointestinal malignancies. In glioblastoma, immunotherapy has not demonstrated an overall survival benefit in individual trials and has, in aggregate analyses, been associated with worse outcomes compared to control arms. Pancreatic adenocarcinoma remains a domain where survival outcomes are dismal, with combination chemotherapy regimens and investigational approaches such as cancer vaccines showing mechanistic promise but falling short of transformative clinical impact. These persistent gaps highlight the continued need for novel therapeutic strategies, refined patient selection, and combination approaches capable of overcoming primary and acquired resistance.

Accelerating Novel Oncology Targets to Patients

Recent oncology research has expanded the therapeutic target landscape well beyond established pathways, with promising candidates emerging across immunology, genomics, epigenetics, and cellular metabolism. These novel targets reflect a broader shift toward precision oncology and mechanistic specificity in drug development.

• Next-generation immune checkpoint targets: Research has moved beyond PD-1 and CTLA-4 to investigate LAG-3, TIM-3, TIGIT, VISTA, BTLA, CD160, and CD96 as actionable checkpoints. In hematologic malignancies specifically, LAG-3, TIM-3, and CD47 are under active investigation. CD155 has emerged as a compelling pan-cancer target, exhibiting specific overexpression across diverse cancer types with high expression strongly associated with poor prognosis; notably, CD155 is significantly upregulated in clinical tumor tissues and cancer cell lines while remaining rarely expressed in normal tissue.

• DNA Damage Response (DDR) pathway expansion: Beyond established PARP inhibitors, a broad set of DDR targets is now being pursued — including ATR, ATM, APE1, DNA-PK, WEE1, CHK1/2, CDC7, PLK4, PKMYT1, Polθ (POLQ), USP1, PARG, WRN, and ALC1 — enabling development of targeted inhibitors and degraders. Synthetic lethality strategies are being extended to DDR-associated targets such as WRN, USP1, ATR, DNA-PK, PRMT5, POLQ, and WEE1.

• Epigenetic regulators: Histone lysine methyltransferases have emerged as an important therapeutic target class, supported by strong evidence linking their dysregulation to cancer progression and acquired drug resistance. Combinatorial epigenetic approaches are also being explored, pairing DNA-demethylating agents with histone deacetylase inhibitors or lysine-specific demethylase inhibitors.

• CAR-T cell therapy target expansion: CD155's pan-cancer overexpression profile positions it as a viable CAR-T cell therapy target, offering a potential strategy for addressing both solid tumors and hematologic malignancies within a single therapeutic framework.

• Metabolic-epigenetic crosstalk: The intersection of metabolic reprogramming and epigenetic dysregulation is being recognized as a tractable therapeutic axis, with the epigenetic-metabolic circuit representing emerging opportunities for intervention across both hematological malignancies and solid tumors.

Overcoming Hurdles in Oncology Drug Development and Access

Oncology drug development continues to be shaped by a complex set of biological and clinical barriers that constrain both treatment efficacy and patient tolerability. Addressing these limitations requires a nuanced understanding of tumor biology, immune dynamics, and pharmacological constraints that inform both clinical decision-making and strategic pipeline planning.

• Therapeutic Resistance: Resistance — whether de novo (intrinsic) or acquired through clonal evolution under selective treatment pressures — remains one of the most defining challenges in oncology. Compensatory signalling pathway activation frequently underlies primary non-response, while acquired resistance drives disease relapse and limits treatment durability, ultimately contributing to poor patient outcomes.

• Tumor Heterogeneity: Both intertumoral heterogeneity (differences between individual tumors) and intratumoral heterogeneity (variations within a single tumor) present significant obstacles to durable cancer eradication. Serial tissue sampling is critical for characterising this variability, yet solid tumor biopsies are invasive, potentially inaccessible, and may still fail to capture the full extent of intratumoral diversity.

• Treatment-Related Toxicity: Chemotherapy-induced neurotoxicity is second only to myelosuppression as a dose-limiting factor, frequently preventing patients from completing a full therapeutic course. Immune checkpoint inhibitors (ICIs) carry their own toxicity burden — immune-related adverse events can precipitate severe complications requiring hospitalisation and may necessitate temporary or permanent ICI discontinuation, creating difficult clinical trade-offs.

• Immunosuppressive Tumor Microenvironment (TME): Tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells collectively establish a profoundly immunosuppressive TME that drives drug resistance and creates a tumor-promoting niche. The abundance of these cell populations is strongly correlated with poor patient prognosis and diminished responsiveness to immunotherapy.

• Dosing and Scheduling Limitations: The inability to maintain continuous pharmacodynamically effective dosing for many targeted agents necessitates intermittent dosing schedules, adding complexity to treatment optimisation and further constraining the therapeutic window available to clinicians.